201 related articles for article (PubMed ID: 19037999)
1. Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-beta receptor inhibitor on extravasation of nanoparticles from neovasculature.
Kano MR; Komuta Y; Iwata C; Oka M; Shirai YT; Morishita Y; Ouchi Y; Kataoka K; Miyazono K
Cancer Sci; 2009 Jan; 100(1):173-80. PubMed ID: 19037999
[TBL] [Abstract][Full Text] [Related]
2. Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway.
Cooke VG; LeBleu VS; Keskin D; Khan Z; O'Connell JT; Teng Y; Duncan MB; Xie L; Maeda G; Vong S; Sugimoto H; Rocha RM; Damascena A; Brentani RR; Kalluri R
Cancer Cell; 2012 Jan; 21(1):66-81. PubMed ID: 22264789
[TBL] [Abstract][Full Text] [Related]
3. Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia.
Hu S; Niu H; Minkin P; Orwick S; Shimada A; Inaba H; Dahl GV; Rubnitz J; Baker SD
Mol Cancer Ther; 2008 May; 7(5):1110-20. PubMed ID: 18483300
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.
Guo T; Agaram NP; Wong GC; Hom G; D'Adamo D; Maki RG; Schwartz GK; Veach D; Clarkson BD; Singer S; DeMatteo RP; Besmer P; Antonescu CR
Clin Cancer Res; 2007 Aug; 13(16):4874-81. PubMed ID: 17699867
[TBL] [Abstract][Full Text] [Related]
5. Molecular dynamics simulation and free energy calculation studies of the binding mechanism of allosteric inhibitors with p38α MAP kinase.
Yang Y; Shen Y; Liu H; Yao X
J Chem Inf Model; 2011 Dec; 51(12):3235-46. PubMed ID: 22097958
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant.
Lierman E; Folens C; Stover EH; Mentens N; Van Miegroet H; Scheers W; Boogaerts M; Vandenberghe P; Marynen P; Cools J
Blood; 2006 Aug; 108(4):1374-6. PubMed ID: 16645167
[TBL] [Abstract][Full Text] [Related]
7. The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro.
von Bubnoff N; Gorantla SP; Engh RA; Oliveira TM; Thöne S; Aberg E; Peschel C; Duyster J
Oncogene; 2011 Feb; 30(8):933-43. PubMed ID: 20972453
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors.
Heinrich MC; Marino-Enriquez A; Presnell A; Donsky RS; Griffith DJ; McKinley A; Patterson J; Taguchi T; Liang CW; Fletcher JA
Mol Cancer Ther; 2012 Aug; 11(8):1770-80. PubMed ID: 22665524
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats.
Abe K; Toba M; Alzoubi A; Koubsky K; Ito M; Ota H; Gairhe S; Gerthoffer WT; Fagan KA; McMurtry IF; Oka M
Am J Respir Cell Mol Biol; 2011 Oct; 45(4):804-8. PubMed ID: 21378262
[TBL] [Abstract][Full Text] [Related]
10. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors.
Kumar R; Crouthamel MC; Rominger DH; Gontarek RR; Tummino PJ; Levin RA; King AG
Br J Cancer; 2009 Nov; 101(10):1717-23. PubMed ID: 19844230
[TBL] [Abstract][Full Text] [Related]
11. The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796.
Dietrich J; Hulme C; Hurley LH
Bioorg Med Chem; 2010 Aug; 18(15):5738-48. PubMed ID: 20621496
[TBL] [Abstract][Full Text] [Related]
12. Diffuse-type gastric carcinoma: progression, angiogenesis, and transforming growth factor beta signaling.
Komuro A; Yashiro M; Iwata C; Morishita Y; Johansson E; Matsumoto Y; Watanabe A; Aburatani H; Miyoshi H; Kiyono K; Shirai YT; Suzuki HI; Hirakawa K; Kano MR; Miyazono K
J Natl Cancer Inst; 2009 Apr; 101(8):592-604. PubMed ID: 19351925
[TBL] [Abstract][Full Text] [Related]
13. Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase.
Kitagawa D; Gouda M; Kirii Y; Sugiyama N; Ishihama Y; Fujii I; Narumi Y; Akita K; Yokota K
J Biochem; 2012 Jan; 151(1):47-55. PubMed ID: 21880693
[TBL] [Abstract][Full Text] [Related]
14. Analysis of imatinib and sorafenib binding to p38alpha compared with c-Abl and b-Raf provides structural insights for understanding the selectivity of inhibitors targeting the DFG-out form of protein kinases.
Namboodiri HV; Bukhtiyarova M; Ramcharan J; Karpusas M; Lee Y; Springman EB
Biochemistry; 2010 May; 49(17):3611-8. PubMed ID: 20337484
[TBL] [Abstract][Full Text] [Related]
15. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling.
Kano MR; Bae Y; Iwata C; Morishita Y; Yashiro M; Oka M; Fujii T; Komuro A; Kiyono K; Kaminishi M; Hirakawa K; Ouchi Y; Nishiyama N; Kataoka K; Miyazono K
Proc Natl Acad Sci U S A; 2007 Feb; 104(9):3460-5. PubMed ID: 17307870
[TBL] [Abstract][Full Text] [Related]
16. Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors.
Chung AS; Kowanetz M; Wu X; Zhuang G; Ngu H; Finkle D; Komuves L; Peale F; Ferrara N
J Pathol; 2012 Aug; 227(4):404-16. PubMed ID: 22611017
[TBL] [Abstract][Full Text] [Related]
17. A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome.
Salemi S; Yousefi S; Simon D; Schmid I; Moretti L; Scapozza L; Simon HU
Allergy; 2009 Jun; 64(6):913-8. PubMed ID: 19210352
[TBL] [Abstract][Full Text] [Related]
18. An adaptive Src-PDGFRA-Raf axis in rhabdomyosarcoma.
Abraham J; Chua YX; Glover JM; Tyner JW; Loriaux MM; Kilcoyne A; Giles FJ; Nelon LD; Carew JS; Ouyang Y; Michalek JE; Pal R; Druker BJ; Rubin BP; Keller C
Biochem Biophys Res Commun; 2012 Sep; 426(3):363-8. PubMed ID: 22960170
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib: muscle wasting.
Prescrire Int; 2011 Dec; 20(122):296-7. PubMed ID: 22216546
[TBL] [Abstract][Full Text] [Related]
20. Tyrosine kinase inhibitors ameliorate autoimmune encephalomyelitis in a mouse model of multiple sclerosis.
Crespo O; Kang SC; Daneman R; Lindstrom TM; Ho PP; Sobel RA; Steinman L; Robinson WH
J Clin Immunol; 2011 Dec; 31(6):1010-20. PubMed ID: 21847523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
